Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Kai Duan,Bende Liu,Cesheng Li,Huajun Zhang,Ting Yu,Jieming Qu,Min Zhou,Li Chen,Shengli Meng,Yong Hu,Cheng Peng,Mingchao Yuan,Jinyan Huang,Zejun Wang,Jianhong Yu,Xiaoxiao Gao,Dan Wang,Xiaoqi Yu,Li Li,Jiayou Zhang,Xiao Wu,Bei Li,Yanping Xu,Wei Chen,Yan Peng,Yeqin Hu,Lianzhen Lin,Xuefei Liu,Shihe Huang,Zhijun Zhou,Lianghao Zhang,Yue Wang,Zhi Zhang,Kun Deng,Zhiwu Xia,Qin Gong,Wei Zhang,Xiaobei Zheng,Ying Liu,Huichuan Yang,Dongbo Zhou,Ding Yu,Jifeng Hou,Zhengli Shi,Saijuan Chen,Zhu Chen,Xinxin Zhang,Xiaoming Yang

DOI: https://doi.org/10.1073/pnas.2004168117

IF: 11.1

2020-04-06

Proceedings of the National Academy of Sciences

Abstract:Significance COVID-19 is currently a big threat to global health. However, no specific antiviral agents are available for its treatment. In this work, we explore the feasibility of convalescent plasma (CP) transfusion to rescue severe patients. The results from 10 severe adult cases showed that one dose (200 mL) of CP was well tolerated and could significantly increase or maintain the neutralizing antibodies at a high level, leading to disappearance of viremia in 7 d. Meanwhile, clinical symptoms and paraclinical criteria rapidly improved within 3 d. Radiological examination showed varying degrees of absorption of lung lesions within 7 d. These results indicate that CP can serve as a promising rescue option for severe COVID-19, while the randomized trial is warranted.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the effectiveness and safety of using convalescent plasma therapy in severe patients with Coronavirus Disease 2019 (COVID - 19). Specifically, the main purpose of the study is to evaluate the safety of a single infusion of 200 milliliters of convalescent plasma (CP) containing high - titer neutralizing antibodies in severe COVID - 19 patients. Secondary objectives include observing the improvement of clinical symptoms and laboratory parameters within 3 days after infusion.

### Research Background
- **Raising of the Problem**: Currently, there are no approved specific antiviral drugs for the treatment of Coronavirus Disease 2019 (COVID - 19). Although some drugs such as Remdesivir and Lopinavir/Ritonavir are under research, the safety and effectiveness of these drugs still need further verification. Therefore, it is particularly urgent to explore alternative treatment strategies, especially for severe patients.
- **History of Convalescent Plasma Therapy**: Convalescent plasma therapy is a classic adaptive immunotherapy, which has been applied to the prevention and treatment of various infectious diseases for more than a century. In recent years, this therapy has achieved satisfactory results and safety in the treatment of SARS, MERS and 2009 H1N1 influenza.

### Research Objectives
- **Primary Endpoint**: Evaluate the safety of convalescent plasma infusion.
- **Secondary Endpoint**: Evaluate the improvement of clinical symptoms and laboratory parameters within 3 days after infusion, including the increase in oxygen saturation, the increase in lymphocyte count and the decrease in C - reactive protein (CRP).

### Research Methods
- **Research Subjects**: 10 severe COVID - 19 patients diagnosed by real - time viral RNA detection.
- **Intervention Measures**: Each patient received a single 200 - milliliter infusion of convalescent plasma from donors who had recently recovered and had a neutralizing antibody titer higher than 1:640.
- **Evaluation Indicators**:
- **Safety**: Record adverse reactions after infusion.
- **Clinical Symptoms**: Observe changes in symptoms such as fever, cough, and dyspnea.
- **Laboratory Parameters**: Monitor changes in lymphocyte count, C - reactive protein, liver function indicators (such as alanine aminotransferase ALT, aspartate aminotransferase AST), total bilirubin TBIL and oxygen saturation SaO₂.
- **Imaging Examinations**: Evaluate the absorption of lung lesions by chest CT.

### Main Findings
- **Safety**: None of the patients had serious adverse reactions, and only one patient had a brief facial erythema.
- **Improvement of Clinical Symptoms**: Within 3 days after infusion, the clinical symptoms of all patients improved significantly, especially symptoms such as fever, cough, dyspnea and chest pain.
- **Changes in Laboratory Parameters**:
- The lymphocyte count increased from 0.65 × 10^9/L to 0.76 × 10^9/L.
- The C - reactive protein decreased from 55.98 mg/L to 18.13 mg/L.
- The oxygen saturation increased from 93.00% to 96.00%.
- **Imaging Changes**: All patients had different degrees of absorption of lung lesions within 7 days after infusion.
- **Viral Load**: Within 7 days after infusion, the previous viremia disappeared in 7 patients.

### Conclusions
- **Preliminary Results**: A single infusion of 200 milliliters of convalescent plasma with high - concentration neutralizing antibodies shows good tolerance and potential therapeutic effects in severe COVID - 19 patients, and can rapidly reduce the viral load and improve clinical symptoms.
- **Future Research Directions**: It is necessary to further explore the optimal dose, infusion time point and the exact clinical benefits of convalescent plasma therapy in larger - scale randomized controlled trials.

### Formula Examples
- **Neutralizing Antibody Titer**: \[ \text{Neutralizing Antibody Titer} = 1:640 \]
- **Lymphocyte Count**: \[ \text{Lymphocyte Count} = 0.65\times 10^9 \text{ cells/L} \]
- **C - reactive Protein**: \[ \text{C - reactive Protein} = 55.98 \text{ mg/L} \]
- **Oxygenation**